+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Liver Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Liver Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896742
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver cancer drugs market is in a pivotal phase, shaped by advances in therapeutic science, evolving operational models, and increasing clinical complexity. Senior leaders navigating this environment must align innovation, supply chain stability, and region-specific strategies to support long-term competitive positioning.

Market Snapshot: Liver Cancer Drugs Market

The Liver Cancer Drugs Market is projected to expand from USD 4.10 billion in 2025 to USD 4.67 billion in 2026, reflecting a CAGR of 14.95%. By 2032, the market is forecasted to reach USD 10.88 billion. Growth is driven by wider adoption of innovative therapies and a strong response to ongoing unmet medical needs in liver oncology. Market drivers include active clinical research efforts, adoption of differentiated technology platforms, and the transition toward patient-centric management models in both developed and emerging regions.

Scope & Segmentation

  • Therapy Modalities: Includes cytotoxic chemotherapy, immunotherapies such as checkpoint inhibitors and cell therapies, targeted agents for specific genetic drivers, and localized radiation strategies.
  • Cancer Types: Covers hepatocellular carcinoma (HCC), cholangiocarcinoma, and pediatric hepatoblastoma, each with distinct diagnostic and clinical management needs.
  • Administration Routes: Spans intravenous infusions for rapid intervention, oral drugs for ongoing home-based care, and subcutaneous formats for improved patient experience.
  • Drug Classes: Consists of cytotoxic drugs, monoclonal antibodies which involve complex production processes, and tyrosine kinase inhibitors requiring specialized monitoring protocols.
  • End Users: Encompasses hospitals, outpatient specialty clinics, and home care environments, all impacting drug delivery and clinical data collection.
  • Distribution Channels: Engages hospital pharmacies, retail and online pharmacies, and strategic delivery networks to support access and treatment adherence.
  • Regions: Addresses Americas, Europe, The Middle East & Africa, and Asia-Pacific, recognizing differences in regulation, reimbursement, and commercial uptake.
  • Key Technologies: Incorporates companion diagnostics, advanced imaging capabilities, digital health platforms, and resilient supply chain approaches for comprehensive care and operational differentiation.

Liver Cancer Drugs Market: Key Takeaways

  • Combination therapy and biomarker-based patient selection are redefining treatment frameworks, moving away from isolated drug strategies to deliver greater specificity in clinical decision-making.
  • Uptake of digital health technologies, such as telehealth and remote monitoring, is streamlining follow-up and supporting improved therapy adherence and patient-reported outcomes.
  • Innovative clinical trial design and regulatory evolution are expediting market access, reducing development timelines for medicines addressing high unmet needs.
  • Supply chain models are adapting in response to increased biologics use and shifting geopolitical landscapes, enhancing agility in manufacturing and delivery systems.
  • Addressing tumor heterogeneity and treatment variation requires tailored engagement pathways for patients and providers, reinforcing the need for targeted solutions.
  • Collaboration between pharmaceutical manufacturers, diagnostic firms, care systems, and advocacy groups is essential for optimizing therapy access, ensuring comprehensive patient support, and driving improved outcomes.

Tariff Impact on Supply and Access

Ongoing updates to global trade and tariff policies add operational complexity for manufacturers and suppliers within the liver cancer drugs market. Adjustments to import duties, evolving customs compliance, and new regulatory requirements are influencing supply costs and reliability. Consequently, many industry players are pursuing near-shoring strategies and revising inventory management protocols. The resilience of this sector depends on adaptive supply chain planning, risk mapping, and consistent stakeholder communication to sustain uninterrupted therapy provision and reduce vulnerability to procurement disruptions.

Methodology & Data Sources

This analysis uses a mixed-methods approach, combining direct interviews with oncologists, regulators, and commercial leaders with a comprehensive review of published research, registry data, and compliance materials. Multiple data sources and internal peer review processes uphold the validity and objectivity of the market findings and insights.

Why This Report Matters

  • Guides senior leaders in calibrating product and market strategies to evolving clinical, regulatory, and operational challenges specific to the liver cancer drugs sector.
  • Enables targeted identification of high-value growth areas, including new therapy segments, geographies, and digital care models aligned with evolving adoption trends.
  • Offers actionable recommendations for integrating biomarker strategies, building strategic payer collaborations, reinforcing resilient supply chains, and advancing patient-focused initiatives.

Conclusion

Sustained success in the liver cancer drugs market will depend on continuous scientific advancement, operational responsiveness, and effective multi-stakeholder partnerships. Strategic alignment to shifts in healthcare demand and proactive risk management will drive industry resilience and support clinical excellence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Liver Cancer Drugs Market, by Therapy Type
8.1. Chemotherapy
8.2. Immunotherapy
8.3. Radiation Therapy
8.4. Targeted Therapy
9. Liver Cancer Drugs Market, by Cancer Type
9.1. Cholangiocarcinoma
9.2. Hepatoblastoma
9.3. Hepatocellular Carcinoma (HCC)
10. Liver Cancer Drugs Market, by Administration Route
10.1. Intravenous
10.2. Oral
10.3. Subcutaneous
11. Liver Cancer Drugs Market, by Drug Class
11.1. Cytotoxic Agents
11.2. Monoclonal Antibodies
11.3. Tyrosine Kinase Inhibitors (TKIs)
12. Liver Cancer Drugs Market, by End User
12.1. Home Care
12.2. Hospital
12.3. Specialty Clinic
13. Liver Cancer Drugs Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy
14. Liver Cancer Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Liver Cancer Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Liver Cancer Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Liver Cancer Drugs Market
18. China Liver Cancer Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Agenus Inc.
19.6. AstraZeneca AB
19.7. AstraZeneca PLC
19.8. Bayer AG
19.9. BeiGene, Ltd.
19.10. Bristol-Myers Squibb Company
19.11. Can-Fite BioPharma Ltd.
19.12. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
19.13. CStone Pharmaceuticals
19.14. Eisai Co., Ltd.
19.15. Eli Lilly and Company
19.16. Exelixis, Inc.
19.17. Hoffmann-La Roche Inc.
19.18. Innovent Biologics, Inc.
19.19. Ipsen SA
19.20. Jiangsu Hengrui Medicine Co., Ltd.
19.21. Merck & Co., Inc.
19.22. Pfizer Inc.
19.23. Roche Holding AG (F. Hoffmann-La Roche Ltd)
19.24. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 96. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 97. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 98. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 110. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 111. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 112. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 126. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 127. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 128. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 132. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 133. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 134. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 146. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 147. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 148. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 153. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 154. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 155. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 160. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 161. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 162. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 163. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 170. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. CHINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 175. CHINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 176. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 177. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 178. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Liver Cancer Drugs market report include:
  • Agenus Inc.
  • AstraZeneca AB
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Hoffmann-La Roche Inc.
  • Innovent Biologics, Inc.
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Roche Holding AG (F. Hoffmann-La Roche Ltd)
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.67 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.88 Billion
Compound Annual Growth Rate14.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Therapeutics - Global Strategic Business Report - Product Image

Liver Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Liver Cancer Therapeutics Market Report 2025 - Product Image

Liver Cancer Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Hepatocellular Carcinoma - Pipeline Insight, 2025 - Product Image

Hepatocellular Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 230 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Liver Cancer Drugs Market

The Liver Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat liver cancer. These drugs are used to reduce the size of tumors, reduce symptoms, and improve the quality of life for those affected by the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells. Immunotherapy is a type of drug that works by stimulating the body's own immune system to fight cancer. The Liver Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly developing new drugs and treatments to improve the quality of life for those affected by liver cancer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.